liver-enriched antimicrobial peptide 2
Peptideexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 28, 2019 (NCT04043065)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Ghrelin receptorANTAGONIST
GHSR antagonist
- Liver-expressed antimicrobial peptide 2Supplementation
LEAP2 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07171723 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2025 | University of Copenhagen |
| NCT04897984 | Early Phase 1 (Phase 1) | May 24, 2021 | University of Copenhagen |
| NCT04621409 | Early Phase 1 (Phase 1) | Oct 29, 2020 | University of Copenhagen |
| NCT04043065 | Early Phase 1 (Phase 1) | Jan 28, 2019 | Gubra ApS, University of Copenhagen |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Copenhagen | Academic/Hospital | 4 | 4 | 2 | 2019 |
| Gubra ApS | For profit | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1